We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New H&E Tissue Staining Solution Sets New Standard in Histopathology

By LabMedica International staff writers
Posted on 07 Dec 2015
A new hematoxylin and eosin (H&E) staining system provides exceptionally high tissue staining quality and efficiency that enhances patient care as well as lab technician safety.

The new “VENTANA HE 600” staining system from Roche (Basel, Switzerland) delivers fresh reagents on each individual slide without relying on user-supplied alcohol and deionized (DI) water, resulting in improved consistency and quality. More...
This individual slide staining technology mitigates the risk of specimen cross-contamination that can occur with other technologies, helping to reduce patient misdiagnosis.

Elimination of xylene and alcohol and utilization of ready-to-use reagents reduce technician exposure to harmful chemicals. Workflow is improved by eliminating the need to manually mix reagents and track product expiration dates. The system offers over 400 individual staining protocols and is highly customizable, allowing for laboratory and pathologist preferences and tissue variables.

In a recent global test, over 4,000 slides from laboratories in 12 countries were stained on VENTANA HE 600 and reviewed by 67 pathologists with excellent results. Evaluation of the criteria, including nuclear detail and stain quality and intensity, resulted in a score of 3.7 on a scale of 4.0.

Robert C. Babkowski, MD, the lead pathologist on a recent 4-week beta-test conducted at Stamford Hospital where he reviewed over 1,000 slides, said, “When we compared our current system, the VENTANA HE 600 system is easier to use, the slides are exquisite, and the consistency is solid. The new system provides beautifully stained slides every time and has allowed me, as a working pathologist, to be even more efficient. Because the instrument is so easy to operate, my histo-technologists are now able to focus on other key histology functions.” Stamford Hospital is one of 4 beta-test sites.

“Approximately 80% of a pathologist's diagnostic report comes from the H&E stain. The VENTANA HE 600 system will help change the standard of care for laboratories, pathologists and, most importantly, cancer patients, who rely heavily on the H&E test,” said Roland Diggelmann, COO, Roche Diagnostics Division, “The system reflects Roche’s commitment to delivering innovation that meets the labs’ needs of today and tomorrow through meaningful advancements in staining quality, patient and laboratory safety, and workflow.”

Related Links:

Roche



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.